Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Positive Phase‑III data push Akeso shares higher

Akeso shares rose nearly 5% to HK$94.8 after full results from the Phase‑III HARMONi‑2 study were presented. The bispecific antibody ivonescimab achieved a median overall survival of 30.8 months versus 22.6 months for pembrolizumab and reduced the risk of death by 27% in PD‑L1–positive, advanced non‑small‑cell lung cancer. The positive market reaction was supported by confirmed buy recommendations from several institutions, and the FDA has accepted a filing for a related indication for review; the PDUFA date is 14 November 2026. » More on de.investing.com
Akeso's ivonescimab cuts risk of death by 34% in China Phase 3 Harmoni-6 trial

Ivonescimab, a PD-1/VEGF bispecific antibody from Akeso (licensed outside China to Summit Therapeutics), reduced the risk of death by 34% when added to chemotherapy in the Harmoni-6 Phase 3 trial in China, yielding median overall survival of 27.9 vs 23.7 months versus PD-1 plus chemotherapy. The result was statistically significant and supports a four-month survival benefit for patients with squamous non-small-cell lung cancer. Safety data showed higher rates of any-grade bleeding (~24% in the ivonescimab arm versus ~12% control) though severe bleeding was under 3%; a global Phase 3 program (Harmoni-3) is ongoing to assess broader applicability. » More on cnbc.com
Summit Therapeutics gains analyst backing as Akeso to disclose HARMONi-6 interim OS at ASCO

Stifel reiterated a Buy rating on Summit Therapeutics with a $45 price target after Akeso said it will disclose an interim overall survival readout from the HARMONi-6 ivonescimab Phase 3 trial at ASCO 2026. HARMONi-6 has a ~33% larger sample size and all-squamous histology versus HARMONi-2, offering a first look at ivonescimab randomized against anti-PD-1 tislelizumab. Summit Therapeutics is developing ivonescimab, a potential first-in-class PD-1/VEGF bispecific antibody for NSCLC. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2021, Akeso has already paid €2.50 in dividends. The last payout was in September 2021.

Financials

In the last quarter, Akeso had revenue of €229.66m and net profit of -€53.96m

(EUR)	June 2026	YoY
Revenue	229.66m	-
Gross profit	170.5m	-
Net profit	-53.96m	-
EBITDA	-53.24m	-

Fundamentals

Metric	Value
Market capitalization	€9.06bn
Number of shares	921.14m
52-week high/low	€17.72 - €9.11
Dividends	No
Beta	0.03
P/E ratio	-70.70
PEG ratio	4.33
P/B ratio	7.96
P/S ratio	19.93

Company profile

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). It is also developing AK105, a PD-1 monoclonal antibody to treat NSCLC, NPC, classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, HNSCC, R/R cHL, NPC, NSCLC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors; and AK109, a VEGFR-2 monoclonal antibody to treat solid tumors and gastric cancer. In addition, the company develops AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis and asthma, and eosinophilic esophagitis; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and MD Anderson Medical Institute. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.